A Phase I Trial of Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab in Patients With Recurrent High Grade Gliomas

Trial Profile

A Phase I Trial of Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab in Patients With Recurrent High Grade Gliomas

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Pembrolizumab (Primary)
  • Indications Anaplastic astrocytoma; Glioblastoma; Glioma
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Nov 2017 Planned number of patients changed from 46 to 55.
    • 30 Jun 2017 Planned number of patients changed from 42 to 46.
    • 30 Jun 2017 Planned End Date changed from 31 Dec 2017 to 31 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top